Last reviewed · How we verify

NCT03519321

Minimal Invasive Deformity Correction (MID-C) System for Early Onset Scoliosis

Status unknown NA Last updated 22 July 2021
What this trial tests

NA trial testing MID-C in Scoliosis in 60 participants. Status unknown.

Timeline
11 April 2018
Primary endpoint
20 June 2023
20 July 2023

Quick facts

Lead sponsorApifix
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment60
Start date11 April 2018
Primary completion20 June 2023
Estimated completion20 July 2023
Sites1 location across Greece

Drugs / interventions tested

Conditions studied

Sponsor

Apifix

Who can join

Adults 6 to 11, any sex, with Scoliosis or Scoliosis Idiopathic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Early Onset Scoliosis (EOS) is defined as scoliosis with onset under the age of ten years, regardless of etiology. It is a complex three-dimensional deformity of the spine which can cause significant physical and psychological problems. Currently there are two basic treatment options available for EOS: non-surgical and surgical. ApiFix Ltd. has developed a novel growing rod system for surgical treatment of EOS, the MID-C system. It is indicated for patients with a scoliosis of 35 to 75 degrees Cobb angle

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of MID-C

Trials testing the same drug.

Other recruiting trials for Scoliosis

Currently open trials in the same condition.

Other Apifix trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03519321.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing